[Effect of fullerene C60 on free-radical induced lipid peroxidation processes in bronchial asthma].

Lipids peroxidative oxidation as well as antioxidative enzymes superoxidedismutase and catalase activity state at the mice sensibilization with ovalbumine, its correction with fulleren FC60 as well as by its forms (FC60-OVA, mFC60 mFC60-OVA) modified and conjugated with ovalbumines have been studied. It has been demonstrated that the mice sensibilization with ovalbumin leads to the tissues peroxidative lipid oxidation processes enforcement as well as lowering antioxidative enzymes activity in lungs and spleen. Used different rulleren forms expressed antioxidative effect and modifying effect to antioxidative protection enzymes at a given pathology. The influence of fulleren FC 60 and its modified form (1,2-methanofulleren-C60)61-carbolacid was the mostly effective. The data recieved testify to the prospects of the fullerens further investigation as the potential medicines.

[Fullerene C60 exhibits immunomodulatory activity during adjuvant-induced arthritis in rats].

The effect of fullerene C60 (FC60) on the immune processes during experimental adjuvant-induced arthritis (AA) in rats has been studied. The results indicate the inhibitory action of FN60 during AA on cellular splenocyte proliferation, neutrophil phagocytic and oxygen-stimulatory activities in the NBT test, and humoral immune mechanisms involved in the production of antinuclear antibodies, formation of circulating immune complexes, and restoration of morphological structure of spleen. Taken together, these results allow FC60 to be considered as a new potential pharmacological agent that can realize its effects mainly through anti-inflammatory and immunomodulatory activity.

[Effect of fullerene C60 on functional activity of phagocytic cells].

The effect of aqueous dispersion of fullerene C60 (FC60) on the functional activity of cells involved in the phagocytosis reactions was studied. FC60 (0.01 microM/l and 0.1 microM/l) produced mainly negative effects on the activity ofnonspecific immunity cells by inhibiting the myeloperoxidase enzymatic activity, decreased the level of induced chemiluminescence, and suppressed the expression of molecules CD54 involved in the adhesion. The only exception was a slight stimulating effect on the NBT test. The results indicate the FC60 influences various stages and mechanisms of phagocytosis.

[The effectiveness of pioglitazone in the treatment of patients with coronary heart disease on the background of metabolic syndrome].

We investigated the effectiveness of pioglitazone in the treatment of patients with coronary heart disease in combination with MS. In the conduct of research revealed that the addition to standard therapy in patients with coronary heart disease on the background of metabolic syndrome pioglitazone led to a reliable slight decrease in body weight, BMI, hip circumference, waist their relationship. Receiving pioglitazone also significantly reduces the concentration of immunoreactive insulin and blood glucose levels, significantly altered lipid metabolism, which generally leads to a lower level of systemic inflammation, metabolism and reduces the severity of insulin resistance. This allows you to recommend the inclusion of pioglitazone in complex coronary heart disease and metabolic syndrome.

[Efficacy of short-term metformin application in complex treatment of patients with coronary artery disease and concomitant metabolic syndrome].

The inclusion of a short course of metformin in complex therapy of coronary artery disease with metabolic syndrome does not alter the clinical features of disease. It had a positive effect on weight loss and the activity of systemic inflammation. The lipid metabolism and insulin resistance were not significantly altered. This results suggest that the treatment with metformin during 1 month in patients with coronary artery disease and metabolic syndrome is sufficient for the manifestation of systemic anti-inflammatory effect of the drug, but not enough to implement a reliable effect of insulin resistance and to improve the clinical features of coronary artery disease.